Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has reported E.P.S. of $0.10 for its third fiscal quarter (ending September 30) versus $0.33 for the same period a year ago — a decline of -70%. This performance was $-0.06 short of the consensus estimate of $0.16. For the latest four quarters through September 30, E.P.S. were $-6.13 compared to $1.07 a year ago — a decline of -673%.
Recent Price Action
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) stock enjoyed a large increase of 3.1% on 11/9/23. The stock closed at $9.52. The stock has risen 5.0% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, IRWD is expected to continue to be a modest Value Builder.
Ironwood Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Ironwood Pharmaceuticals has a neutral Appreciation Score of 60 and a slightly negative Power Rating of 30, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment